Cargando…

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries....

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyer, Arnaud, Pasquier, Eddy, Tomasini, Pascale, Ciccolini, Joseph, Greillier, Laurent, Andre, Nicolas, Barlesi, Fabrice, Mascaux, Celine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488560/ https://www.ncbi.nlm.nih.gov/pubmed/29540495 http://dx.doi.org/10.1183/16000617.0098-2017

Ejemplares similares

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
por: Tomasini, Pascale, et al.
Publicado: (2016)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
por: Imbs, Diane‐Charlotte, et al.
Publicado: (2017)

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma
por: Staumont, Bernard, et al.
Publicado: (2020)

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
por: Elharrar, Xavier, et al.
Publicado: (2016)

A breath of fresh air.
Publicado: (1994)

A breath of fresh air!
por: Anaïs Schaeffer
Publicado: (2013)

A breath of fresh air
por: McCarthy, Sam
Publicado: (2021)

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
por: Benzekry, Sébastien, et al.
Publicado: (2021)

A breath of not so fresh air…
por: Pinto Pereira, João, et al.
Publicado: (2022)

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
por: Mogenet, Alice, et al.
Publicado: (2021)

Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review
por: Töreyin, Zehra Nur, et al.
Publicado: (2020)

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
por: Jean, Fanny, et al.
Publicado: (2017)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

A breath of fresh air for cryogenics training
por: HSE Unit
Publicado: (2014)

A Breath of Fresh Air for Clinical Diagnoses
por: Beauchamp, Jonathan D.
Publicado: (2015)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

A breath of fresh air – the potential for COVID-19 breath diagnostics
por: Davis, Cristina E., et al.
Publicado: (2021)

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
por: Janssens, Eline, et al.
Publicado: (2022)

The turbulent future brings a breath of fresh air
por: Stjern, Camilla W., et al.
Publicado: (2023)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
por: Ciccolini, Joseph, et al.
Publicado: (2020)

GI distress: A breath of fresh air in respiratory homeostasis
por: Kinkead, Richard, et al.
Publicado: (2019)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

Time for a breath of fresh air: Rethinking training in airway management
por: Marshall, S. D., et al.
Publicado: (2016)

An Extra Breath of Fresh Air: Hyperbaric Oxygenation as a Stroke Therapeutic
por: Cozene, Blaise, et al.
Publicado: (2020)

Breathing fresh air into respiratory research with single-cell RNA sequencing
por: Alexander, Michael J., et al.
Publicado: (2020)

Breath of Fresh Air: Toward Unraveling the Molecular Underpinnings of Sleep Apnea
por: Cade, Brian E., et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lof7iq0flpl7a064ucle32jcs6